Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...

Vaccines are one of the most important medical inventions of modern times that have saved and enhanced innumerable lives around the world. Despite the technological advances in vaccine design and ...

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.

Half of the individuals with genital herpes simplex virus (HSV) infection experience several recurrence episodes per year, especially if the causative agent is HSV type 2 (HSV-2). Standard-of-care ...

The World Health Organization (WHO) recently released new estimates suggesting around 846 million people aged between 15 and 49 live with a genital herpes infection. That's equivalent to one in every ...

Unveiling a global crisis: groundbreaking research highlights the immense impact of HSV infections on health, urging a shift towards vaccine innovation and prevention measures. Study: Estimated global ...

Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and ...